Ibritumomab tiuxetan (IDEC-129) is an antibody targeting CD20, conjugated to a radioactive isotope via a chelating agent Tiuxetan, and can be used in radioimmunotherapy.
Purity:
0.9866
CAS Number:
[206181-63-7]
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted